Background: The aim of this research was to study PIK3CA mutation depending tumor response to concurrent chemoradiotherapy among Azerbaijanian cervical cancer patients. Materials and Methods: The authors investigated treatment results of 136 Stage IB-IVA cervical cancer patients. Treatment consisted of external beam radiotherapy, weekly cisplatin, and high-dose rate brachytherapy. PIK3CA gene mutations were detected using PIK3CA mutation analysis kit. The association of genetic alterations with clinicopathological characteristics and treatment response were analyzed. Results: The authors revealed activation of PIK3CA gene in 49 (36%) patients in total. PIK3CA mutations were found in five (10.2%) cases of adenocarcinomas and in 44 (89.8%) patients with squamous cell cervical cancer. Of the 136 patients retrieved in this study, 112 (82,3%) patients had complete response, 23 (18,7%) had partial response, and only one had progression of the disease. The frequency of compete response was significantly lower in PIK3CA mutation positive patients (77.6% vs. 92%, p = 0,035). Conclusion: The authors revealed some association between PIK3CA gene alterations and tumor response after chemoradiotherapy in patients with locally advanced cervical cancer. More than one-third of cervical cancer patients are PIK3CA gene mutations carriers and in the future potentially could benefit from newly discovered therapeutic agents which directly target PIK3CA.